Publication:
Immunohistochemistry for differentiation of pleural epithelioid malignant mesothelioma from adenocarcinoma: A panel for selection

dc.contributor.authorAkyıldız, Elif Ülker
dc.contributor.authorÖz, Buge
dc.contributor.authorAki, Hilal
dc.contributor.authorDemirkaya, Ahmet
dc.contributor.buuauthorAKYILDIZ, ELİF ÜLKER
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Patoloji Anabilim Dalı.
dc.contributor.researcheridJHY-9777-2023
dc.date.accessioned2024-10-16T11:08:20Z
dc.date.available2024-10-16T11:08:20Z
dc.date.issued2010-12-01
dc.description.abstractObjective: An important difficulty pathologists confront concerning thoracic pathology is the differentiation of pleural epithelioid malignant mesothelioma from pulmonary adenocarcinoma infiltrating into the pleura or metastatic adenocarcinoma. Since epithelioid malignant mesothelioma may depict microscopic patterns similar to adenocarcinoma, morphological findings may not be sufficient to make a differential diagnosis. Up to now, many immunohistochemical markers have been proposed for their differentiation and there have been many studies on the sensitivity and specifity of each marker.Material and Method: In this study we retrospectively evaluated the reports on patients diagnosed as pleural epithelial MM and patients diagnosed as adenocarcinoma infiltrating into the pleura for the past seven years and determined the immunohistochemical markers used for differential diagnosis.Results: Most frequently used markers were calretinin and CK5/6 for epithelioid malignant mesothelioma and CEA, CD15 and TTF-1 for adenocarcinoma. EMA was used in both groups.Conclusion: We found that a panel including calretinin and CK5/6 for malignant mesothelioma and CEA and CD15 for adenocarcinoma and additionally EMA and TTF-1 avoided the difficulty in all cases. We consider that, if there is any inconsistency between the results of staining with these six markers, other antibodies should be incorporated into the panel.
dc.identifier.doi10.5152/ttd.2010.23
dc.identifier.endpage148
dc.identifier.issn1302-7808
dc.identifier.issue4
dc.identifier.startpage144
dc.identifier.urihttps://doi.org/10.5152/ttd.2010.23
dc.identifier.urihttps://thoracrespract.org/en/immunohistochemistry-for-differentiation-of-pleural-epithelioid-malignant-mesothelioma-from-adenocarcinoma-a-panel-for-selection-13566
dc.identifier.urihttps://hdl.handle.net/11452/46529
dc.identifier.volume11
dc.identifier.wos000421708700002
dc.indexed.wosWOS.ESCI
dc.language.isoen
dc.publisherBilimsel Tıp Publishing House
dc.relation.journalTurkish Thoracic Journal
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectMalignant mesothelioma
dc.subjectAdenocarcinoma
dc.subjectImmunohistochemistry
dc.subjectRespiratory system
dc.titleImmunohistochemistry for differentiation of pleural epithelioid malignant mesothelioma from adenocarcinoma: A panel for selection
dc.typeArticle
dspace.entity.typePublication
relation.isAuthorOfPublicationa6528db3-6c7b-4f9f-a03d-e9ad2017907e
relation.isAuthorOfPublication.latestForDiscoverya6528db3-6c7b-4f9f-a03d-e9ad2017907e

Files

Collections